

Theodoros Foukakis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1894020/theodoros-foukakis-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91
papers

2,865
citations

26
h-index

53
g-index

102
ext. papers

4,065
ext. citations

7.1
avg, IF

5.14
L-index

#	Paper	IF	Citations
91	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 810-821	59.2	599
90	Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. <i>Cell</i> , 2018 , 173, 879-893.e13	56.2	427
89	An HIF-1 α /VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. <i>Cancer Cell</i> , 2017 , 32, 669-683.e54.3	54.3	207
88	Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4440-5	5.6	187
87	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <i>Oncogene</i> , 2018 , 37, 4639-4661	9.2	133
86	Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. <i>Nature Communications</i> , 2017 , 8, 228	17.4	79
85	Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(γ) fusion oncogene. <i>Oncogene</i> , 2005 , 24, 1467-76	9.2	63
84	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 127-138	21.7	62
83	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1888-1896	27.4	58
82	Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 553-60	4.4	56
81	External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. <i>JAMA Oncology</i> , 2020 , 6, 1581-1588	13.4	55
80	First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. <i>Radiotherapy and Oncology</i> , 2015 , 114, 322-7	5.3	44
79	Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. <i>Clinical Cancer Research</i> , 2019 , 25, 5717-5726	12.9	43
78	Molecular markers for discrimination of benign and malignant follicular thyroid tumors. <i>Tumor Biology</i> , 2006 , 27, 211-20	2.9	42
77	Advances in the treatment of patients with gastric adenocarcinoma. <i>Acta Oncologica</i> , 2007 , 46, 277-85	3.2	42
76	Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. <i>Oncotarget</i> , 2016 , 7, 74966-74978	3.3	42
75	Proteomic profiling of follicular and papillary thyroid tumors. <i>European Journal of Endocrinology</i> , 2012 , 166, 657-67	6.5	39

74	A PCR-based expression signature of malignancy in follicular thyroid tumors. <i>Endocrine-Related Cancer</i> , 2007 , 14, 381-91	5.7	39
73	Array-CGH identifies cyclin D1 and UBC10 amplicons in anaplastic thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2008 , 15, 801-15	5.7	37
72	The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1143-9	5.6	35
71	Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. <i>Cancers</i> , 2019 , 11,	6.6	34
70	Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. <i>Thyroid</i> , 2007 , 17, 289-301	6.2	34
69	STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	32
68	Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. <i>Clinical Cancer Research</i> , 2017 , 23, 7512-7520	12.9	27
67	Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution. <i>Journal of Surgical Oncology</i> , 2012 , 106, 981-6	2.8	27
66	The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. <i>Breast Cancer Research</i> , 2019 , 21, 34	8.3	26
65	Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca ²⁺ -binding protein S100A6 in papillary thyroid carcinoma. <i>Thyroid</i> , 2010 , 20, 1067-76	6.2	26
64	The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. <i>Endocrine-Related Cancer</i> , 2007 , 14, 125-34	5.7	24
63	Immune gene expression and response to chemotherapy in advanced breast cancer. <i>British Journal of Cancer</i> , 2018 , 118, 480-488	8.7	20
62	Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 407-14	4.4	20
61	Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?. <i>Annals of Oncology</i> , 2019 , 30, 1044-1050	10.3	16
60	A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. <i>Acta Oncologica</i> , 2015 , 54, 522-9	3.2	15
59	Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial. <i>Oncologist</i> , 2020 , 25, 23-32	5.7	14
58	Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1573-9	2.2	13
57	Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. <i>Molecular Oncology</i> , 2016 , 10, 517-25	7.9	13

56	Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 501-501	2.2	12
55	Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 114, 91-101	7	11
54	Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study. <i>Npj Breast Cancer</i> , 2020 , 6, 36	7.8	11
53	Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 958-967	4	10
52	Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. <i>Oncolmmunology</i> , 2018 , 7, e1466017	7.2	10
51	Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients. <i>Annals of Oncology</i> , 2019 , 30, 109-114	10.3	10
50	Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. <i>Molecular Oncology</i> , 2015 , 9, 1384-91	7.9	9
49	Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. <i>Molecular Oncology</i> , 2020 , 14, 951-963	7.9	9
48	Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. <i>BMC Cancer</i> , 2013 , 13, 473	4.8	8
47	Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102257	14.4	8
46	Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E9635-E9644	11.5	7
45	An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 2417-26	12.9	7
44	Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , 2020 , 126, 1175-1182	6.4	7
43	Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. <i>Acta Oncologica</i> , 2017 , 56, 1143-1151	3.2	6
42	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2017 , 23, 7225-7231	12.9	6
41	PD-1 protein and gene expression as prognostic factors in early breast cancer. <i>ESMO Open</i> , 2020 , 5, e001032	10.3	6
40	Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. <i>Acta Oncologica</i> , 2020 , 59, 1382-1387	3.2	6
39	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. <i>Acta Oncologica</i> , 2020 , 59, 75-81	3.2	6

38	Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 319-326	3.5	5
37	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 349-355	4.4	5
36	Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. <i>Clinical Nutrition</i> , 2021 , 40, 3370-3378	5.9	5
35	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019 , 120, 959-967	8.7	3
34	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 87-96	4.4	3
33	Validation of a novel procedure for quantification of the formation of phosphoramidate mustard by individuals treated with cyclophosphamide. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 549-58	3.5	3
32	Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 703-712	4.4	3
31	A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in Stockholm, Sweden.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10083-10083	2.2	2
30	Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 553-553	2.2	2
29	Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 583-583	2.2	2
28	Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. <i>Cancers</i> , 2022 , 14, 2615	6.6	2
27	Chemotherapy use near the end-of-life in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 645-651	4.4	1
26	Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors 2005 , 26, 141		1
25	Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 538-538	2.2	1
24	Expert Discussion: HER2-Positive Breast Cancer. <i>Breast Care</i> , 2021 , 16, 422-428	2.4	1
23	Ribociclib in premenopausal women with advanced breast cancer. <i>Lancet Oncology</i> , 2018 , 19, 850-852	7	1
22	Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1360-1367	13.4	1
21	Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors. <i>International Journal of Oncology</i> , 2005 , 26, 141-9	1	1

20	Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. <i>Npj Breast Cancer</i> , 2021 , 7, 144	7.8	o
19	Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines. <i>British Journal of Surgery</i> , 2021 , 108, 1120-1125	5.3	o
18	Reply to A.Y. Lin. <i>Journal of Clinical Oncology</i> , 2017 , 35, 121-122	2.2	
17	RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 1280-1281	9.7	
16	338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study 2021 , 9, A364-A364		
15	Prognostic implications of PD-L1 expression in breast cancer at the protein and mRNA levels.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14284-e14284	2.2	
14	Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2- early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 550-550	2.2	
13	One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 590-590	2.2	
12	PD-1 protein and gene expression in early breast cancer: Prognostic implications.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 545-545	2.2	
11	Sequential metastatic biopsies and functional imaging in breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22120-e22120	2.2	
10	Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22090-e22090	2.2	
9	Gene expression of metastatic biopsies for prediction of response to palliative chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1044-1044	2.2	
8	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004 ¹ (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12036-e12036	2.2	
7	Regulation of PD-L1 in breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23088-e23088	2.2	
6	Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e11510-e11510	2.2	
5	Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation. <i>Npj Breast Cancer</i> , 2021 , 7, 21	7.8	
4	Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial. <i>Cancer Research</i> , 2022 , 82, P4-12-01-P4-12-01	10.1	
3	Abstract P1-02-03: Tumor-infiltrating lymphocytes but not HER2 copy number or ratio show prognostic value in trastuzumab-treated HER2-positive breast cancer. <i>Cancer Research</i> , 2022 , 82, P1-02-03-P1-02-03	10.1	

2 Pathogenesis of Thyroid Cancer 124-129

1 Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study.. *Breast Cancer Research and Treatment*, 2022, 1 4-4